Gilead Sciences is scheduled to report second-quarter results on August 4 after market close, with the Zacks Consensus Estimate for sales at $7.37 billion and a loss per share of $7.07. The company's HIV franchise remains a key driver, led by Biktarvy with a consensus sales estimate of $3.6 billion and Descovy at $750 million, while the newly launched injectable PrEP therapy Yeztugo is expected to show strong growth after first-quarter sales of $166 million and a raised 2026 guidance of $1 billion. However, cell therapy products Yescarta and Tecartus are likely to see lower sales due to competitive pressures, with consensus estimates at $417 million, and Trodelvy sales are pegged at $448 million. Gilead shares have risen 9.4% year to date, outperforming the industry, and the stock trades at 25.48 times forward earnings, above its historical mean but below the large-cap pharma industry average.
Gilead Sciences IncQ2 earnings report with mixed expectations: strong HIV sales but cell therapy headwinds and competitive pressures.
GSK plc
Merck & Company Inc